ArticleNuclear medicine and biology
Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.
Article in Nuclear medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Advances in neurotensin receptor 1-targeted molecular probes for tumor molecular imaging and therapy.Frontiers in oncology · 2026Review
- Establishing Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory.EJNMMI radiopharmacy and chemistry · 2025Article
- Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Radiocobalt theranostic applications: current landscape, challenges, and future directions.Frontiers in nuclear medicine · 2025Review
- Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals.Angewandte Chemie (International ed. in English) · 2024Article
- Synthesis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [Bioconjugate chemistry · 2024Article
- Preclinical evaluation of [Scientific reports · 2023Article
- Separation of cyclotron-produced cobalt-55/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Neurotensin receptor 1 (NTSR1) can stimulate tumor proliferation through neurotensin (NTS) activation and are overexpressed by a variety of cancers. The high binding affinity of NTS/NTSR1 makes radiolabeled NTS derivatives interesting for cancer diagnosis and staging. Internalization of NTS/NTSR1 also suggests therapeutic application with high LET alpha particles and low energy electrons. We investigated the therapeutic efficacy of [
methodsTargeting properties and cytotoxicity of [
resultsHPLC measured radiochemical purity of [
conclusionThe enhanced in vitro cytotoxicity and high tumor-to-background led us to investigate the therapeutic efficacy of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.